— Know what they know.
Not Investment Advice
Also trades as: NRSN (NASDAQ) · $vol 0M

NRSNW NASDAQ

NeuroSense Therapeutics Ltd.
1W: -51.9% 1M: +10.2% 3M: -51.9% YTD: -66.8% 1Y: -60.0% 3Y: -58.3%
$0.10
+0.04 (+66.67%)
 
Weekly Expected Move ±187.2%
$-0 $-0 $0 $0 $0
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 41 · $2.5M mcap · 16M float · 0.0070% daily turnover · Short 60% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$2.5M
52W Range0.0697-0.3
Volume3,868
Avg Volume1,122
Beta1.56
Dividend
Analyst Ratings
No analyst coverage
Company Info
CEOAlon Ben-Noon
Employees16
SectorHealthcare
IndustryBiotechnology
IPO Date2021-12-09
Medinat ha-Yehudim Street 85
Herzliya, TA 4676670
IL
972 9 953 1142
About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology firm dedicated to pioneering novel therapies for severe neurodegenerative conditions. Its most advanced investigational asset is PrimeC, an innovative oral compound specifically engineered to address amyotrophic lateral sclerosis (ALS). Beyond its lead program, the company boasts a preclinical pipeline featuring StabiliC, aimed at Parkinson's disease, and CogniC, targeting Alzheimer's disease. Established in Herzliya, Israel, in 2017, NeuroSense Therapeutics continues to advance its therapeutic initiatives.

Recent Insider Trades

NameTypeSharesPriceDate
Eisenberg Or A-Award 200,000 2026-03-26
Russek-Blum Niva A-Award 200,000 2026-03-26
Binder Hagit A-Award 200,000 2026-03-26
Eisenberg Or 0 2026-03-18
Eisenberg Or 0 2026-03-18

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms